What is the appropriate workup for a patient with bilateral lower extremity polyneuropathy confirmed on electromyography (EMG)?

Workup for Bilateral Lower Extremity Polyneuropathy Confirmed on EMG

For a patient with EMG-confirmed bilateral lower extremity polyneuropathy, perform screening laboratory tests including blood glucose, serum B12 with metabolites (methylmalonic acid and homocysteine), and serum protein immunofixation electrophoresis, as these have the highest diagnostic yield. 1, 2

Initial Laboratory Screening

The following tests should be ordered for all patients with confirmed polyneuropathy:

High-Yield Tests (Priority)

• Blood glucose or hemoglobin A1c - Diabetes and pre-diabetes account for a substantial proportion of polyneuropathy cases 1, 2
• Serum B12 with metabolites - Must include methylmalonic acid (more specific) with or without homocysteine, as serum B12 alone can miss deficiency when levels are in the low-normal range 1, 2
• Serum protein immunofixation electrophoresis (IFE) - More sensitive than standard SPEP for detecting monoclonal gammopathies, which occur in 10% of polyneuropathy patients 1, 2

Additional Screening Tests

• Complete blood count 2
• Comprehensive metabolic panel (includes renal function, electrolytes) 2
• Erythrocyte sedimentation rate 2
• Thyroid function tests (TSH) 2

Secondary Testing Based on Initial Results

If Fasting Glucose is Normal

Consider glucose tolerance testing (GTT), particularly if the patient has painful sensory symptoms, as 25-36% of patients with idiopathic distal symmetric polyneuropathy have impaired glucose tolerance despite normal routine glucose testing 1, 2

If B12 Metabolites are Elevated

• Methylmalonic acid elevation (98.4% sensitive) is more specific for B12 deficiency than homocysteine (95.9% sensitive) 1
• Note that homocysteine can be elevated in folate deficiency (91%), pyridoxine deficiency, renal insufficiency, hypothyroidism, and hypovolemia 1

Genetic Testing Considerations

Genetic testing should be considered if the patient exhibits a hereditary neuropathy phenotype (slowly progressive course, pes cavus, hammer toes, family history) even without a clear family history 1, 2

Approach to Genetic Testing

• First, determine if the neuropathy is primarily demyelinating or axonal based on the EMG findings 1
• Initial genetic panel should focus on the most common mutations:
  • CMT1A duplication/HNPP deletion (most common hereditary neuropathy) 1, 3
  • Cx32 (GJB1) mutation for X-linked cases 1, 3
  • MFN2 mutation for axonal forms 1, 3
• There is insufficient evidence to support routine genetic testing in patients without a classical hereditary phenotype 1

Special Diagnostic Considerations

For Suspected Small Fiber Neuropathy

If the patient has prominent pain, burning, or autonomic symptoms with normal or minimally abnormal EMG findings, consider skin biopsy with intraepidermal nerve fiber (IENF) density measurement 1, 2

• Skin biopsy using PGP 9.5 immunohistochemistry is a validated technique for documenting small fiber loss 1
• This is particularly useful when large fiber testing (EMG/NCS) is normal but clinical suspicion remains high 1

For Suspected Autonomic Involvement

Autonomic testing (heart rate variability with deep breathing, Valsalva maneuver, quantitative sudomotor axon reflex test) should be considered if the patient has orthostatic symptoms, abnormal sweating, or other autonomic complaints 1, 2

Tests with Low Yield (Generally Not Recommended)

• Cerebrospinal fluid analysis has low diagnostic yield except when demyelinating polyneuropathy (such as CIDP) is suspected 2
• Nerve biopsy should be reserved only for cases where vasculitis or specific inflammatory conditions are strongly suspected 2
• Bilateral lower extremity nerve conduction studies may have limited additional utility, as unilateral studies show significant agreement (κ = 0.77) with bilateral findings 4

Critical Pitfalls to Avoid

• Do not rely on serum B12 levels alone - Always order metabolites (methylmalonic acid ± homocysteine), as 44% of B12-deficient patients have normal serum B12 levels 1
• Do not use standard SPEP instead of immunofixation - IFE detects 30% more IgM monoclonal gammopathies, particularly small ones 1
• Do not skip glucose tolerance testing if fasting glucose is normal - This is especially important in patients with painful sensory polyneuropathy 1, 2
• Do not order extensive laboratory panels without clinical correlation - Laboratory testing alone has only 37% diagnostic yield without proper clinical context 2

Additional Testing Based on Clinical Context

While the above tests represent the evidence-based screening approach, additional targeted testing may be warranted based on specific clinical features (e.g., ANA for suspected vasculitis, heavy metal screening for occupational exposure, HIV testing for risk factors) 1, 2